Search Results - "Brighton, Timothy A."

Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism by Brighton, Timothy A, Eikelboom, John W, Mann, Kristy, Mister, Rebecca, Gallus, Alexander, Ockelford, Paul, Gibbs, Harry, Hague, Wendy, Xavier, Denis, Diaz, Rafael, Kirby, Adrienne, Simes, John

“…Low-Dose Aspirin and Recurrent Thromboembolism Results from the ASPIRE trial add evidence supporting the use of low-dose daily aspirin for preventing recurrent…”
Get full text

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis by Khan, Faizan, Rahman, Alvi, Carrier, Marc, Kearon, Clive, Weitz, Jeffrey I, Schulman, Sam, Couturaud, Francis, Eichinger, Sabine, Kyrle, Paul A, Becattini, Cecilia, Agnelli, Giancarlo, Brighton, Timothy A, Lensing, Anthonie W A, Prins, Martin H, Sabri, Elham, Hutton, Brian, Pinede, Laurent, Cushman, Mary, Palareti, Gualtiero, Wells, George A, Prandoni, Paolo, Büller, Harry R, Rodger, Marc A

“…AbstractObjectivesTo determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients…”
Get full text

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma by Brighton, Timothy A, Khot, Amit, Harrison, Simon J, Ghez, David, Weiss, Brendan M, Kirsch, Andres, Magen, Hila, Gironella, Mercedes, Oriol, Albert, Streetly, Matthew, Kranenburg, Britte, Qin, Xiang, Bandekar, Rajesh, Hu, Peter, Guilfoyle, Mary, Qi, Ming, Nemat, Sepideh, Goldschmidt, Hartmut

“…IL6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL6 with siltuximab to delay the transition from high-risk…”
Get full text

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies by Prins, Martin H, Lensing, Anthonie Wa, Bauersachs, Rupert, van Bellen, Bonno, Bounameaux, Henri, Brighton, Timothy A, Cohen, Alexander T, Davidson, Bruce L, Decousus, Hervé, Raskob, Gary E, Berkowitz, Scott D, Wells, Philip S

“…Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been…”
Get full text

Paris-Trousseau thrombocytopenia is phenocopied by the autosomal recessive inheritance of a DNA-binding domain mutation in FLI1 by Stevenson, William S., Rabbolini, David J., Beutler, Lucinda, Chen, Qiang, Gabrielli, Sara, Mackay, Joel P., Brighton, Timothy A., Ward, Christopher M., Morel-Kopp, Marie-Christine

“…Hemizygous deletion of a variable region on chromosome 11q containing FLI1 causes an inherited platelet-related bleeding disorder in Paris-Trousseau…”
Get full text

Risk of recurrent venous thromboembolism according to baseline risk factor profiles by Prins, Martin H., Lensing, Anthonie W.A., Prandoni, Paolo, Wells, Philip S., Verhamme, Peter, Beyer-Westendorf, Jan, Bauersachs, Rupert, Bounameaux, Henri, Brighton, Timothy A., Cohen, Alexander T., Davidson, Bruce L., Decousus, Hervé, Kakkar, Ajay K., van Bellen, Bonno, Pap, Akos F., Homering, Martin, Tamm, Miriam, Weitz, Jeffrey I.

“…The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In this prespecified analysis, we used data from 2 randomized trials,…”
Get full text

Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration by Simes, John, Becattini, Cecilia, Agnelli, Giancarlo, Eikelboom, John W, Kirby, Adrienne C, Mister, Rebecca, Prandoni, Paolo, Brighton, Timothy A

“…In patients with a first unprovoked venous thromboembolism (VTE) the risk of recurrent VTE remains high after anticoagulant treatment is discontinued. The…”
Get full text

Serotonin Release Assay: Functional Assay for Heparin- and Vaccine-Induced (Immune) Thrombotic Thrombocytopenia by Kondo, Mayuko, Donikian, Dea, Brighton, Timothy A

“…The serotonin release assay (SRA) has been the gold-standard assay for detection of heparin-dependent platelet-activating antibodies and integral for the…”
Get more information

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis by Khan, Faizan, Rahman, Alvi, Carrier, Marc, Kearon, Clive, Schulman, Sam, Couturaud, Francis, Prandoni, Paolo, Eichinger, Sabine, Becattini, Cecilia, Agnelli, Giancarlo, Büller, Harry R, Brighton, Timothy A, Palareti, Gualtiero, Pinede, Laurent, Sabri, Elham, Hutton, Brian, Wells, George A, Rodger, Marc A

“…IntroductionFor patients with a first unprovoked venous thromboembolism (VTE), the optimal duration of anticoagulation is a crucial clinical dilemma which has…”
Get full text

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Martinelli, Ida, Lensing, Anthonie W.A., Middeldorp, Saskia, Levi, Marcel, Beyer-Westendorf, Jan, van Bellen, Bonno, Bounameaux, Henri, Brighton, Timothy A., Cohen, Alexander T., Trajanovic, Mila, Gebel, Martin, Lam, Phuong, Wells, Philip S., Prins, Martin H.

“…Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown whether the use of…”
Get full text

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin by Davidson, Bruce L, Verheijen, Sara, Lensing, Anthonie W A, Gebel, Martin, Brighton, Timothy A, Lyons, Roger M, Rehm, Jeffrey, Prins, Martin H

“…Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined…”
Get more information

Platelet function testing in uraemic patients by Ho, Shir-Jing, Gemmell, Rosalie, Brighton, Timothy A

“…Chronic renal failure (CRF) is associated with excessive bleeding for a variety of reasons. Platelet dysfunction is probably the most consistent and important…”
Get more information

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study by Weitz, Jeffrey I, Bauersachs, Rupert, Beyer-Westendorf, Jan, Bounameaux, Henri, Brighton, Timothy A, Cohen, Alexander T, Davidson, Bruce L, Holberg, Gerlind, Kakkar, Ajay, Lensing, Anthonie W A, Prins, Martin, Haskell, Lloyd, van Bellen, Bonno, Verhamme, Peter, Wells, Philip S, Prandoni, Paolo

“…Patients with unprovoked venous thromboembolism (VTE) are at high risk for recurrence. Although rivaroxaban is effective for extended VTE treatment at a dose…”
Get more information

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension by Wells, Philip S, Prins, Martin H, Levitan, Bennett, Beyer-Westendorf, Jan, Brighton, Timothy A, Bounameaux, Henri, Cohen, Alexander T, Davidson, Bruce L, Prandoni, Paolo, Raskob, Gary E, Yuan, Zhong, Katz, Eva G, Gebel, Martin, Lensing, Anthonie W A

“…Short-term anticoagulant treatment for acute DVT or pulmonary embolism (PE) effectively reduces the risk of recurrent disease during the first 6 to 12 months…”
Get full text

Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study by Morel-Kopp, Marie-Christine, Tan, Chee Wee, Brighton, Timothy A, McRae, Simon, Baker, Ross, Tran, Huyen, Mollee, Peter, Kershaw, Geoffrey, Joseph, Joanne, Ward, Christopher

“…Heparin-induced thrombocytopenia (HIT) remains a challenge, with diagnosis confirmed only by functional assays. The gold standard 14C-serotonin release assay…”
Get more information

Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms by Lee, Christine S.M., Clarke, Lisa J., Kershaw, Geoffrey W., Tohidi-Esfahani, Ibrahim, Brighton, Timothy A., Chunilal, Sanjeev, Favaloro, Emmanuel J., Tran, Huyen, Chen, Vivien M.

“…Anti-platelet factor 4 (PF4) antibodies in vaccine-induced immune thrombotic thrombocytopenia (VITT) appear to be transient, with discrepant persistence…”
Get full text

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE by Wells, Philip S., MD, Prins, Martin H., MD, PhD, Levitan, Bennett, MD, PhD, Beyer-Westendorf, Jan, MD, Brighton, Timothy A., MD, Bounameaux, Henri, MD, Cohen, Alexander T., MD, Davidson, Bruce L., MD, MPH, Prandoni, Paolo, MD, PhD, Raskob, Gary E., PhD, Yuan, Zhong, MD, PhD, Katz, Eva G., PhD, MPH, Gebel, Martin, PhD, Lensing, Anthonie W.A., MD, PhD

“…Background Short-term anticoagulant treatment for acute DVT or pulmonary embolism (PE) effectively reduces the risk of recurrent disease during the first 6 to…”
Get full text

The direct factor Xa inhibitor rivaroxaban by Verma, Abhishek K, Brighton, Timothy A

“…Warfarin and heparin are the traditional mainstay anticoagulant therapies for treating thromboembolic disease. These drugs, with a documented history of…”
Get full text

The direct thrombin inhibitor melagatran/ximelagatran by Brighton, Timothy A

“…Melagatran is a synthetic, small‐peptide direct thrombin inhibitor with anticoagulant activity. Ximelagatran, an oral prodrug, undergoes rapid enzymatic…”
Get full text

Platelet activation in the hypertensive disorders of pregnancy by Harlow, Françoise H., Brown, Mark A., Brighton, Timothy A., Smith, Susan L., Trickett, Annette E., Kwan, Y-L, Davis, Gregory K.

“…Objective: The purpose of this study was to determine whether platelet activation occurs only in preeclampsia or also in normal pregnancy. Study Design: Thirty…”
Get full text